I would back $LHX for the next quarter. CVNA has impressive volume growth and LLY continues to benefit from strong weight-loss drug demand, but LHX offers something particularly attractive: long-term revenue visibility.


Its Q3 backlog reached a record $53.2 billion, up 47% year-on-year, with a 3.2x book-to-bill ratio. Free cash flow also increased 195% to $1.3 billion, giving the growth story more financial support.


I would consider buying a pullback after the earnings rally, rather than chasing the initial price reaction. My key trigger would be backlog conversion into revenue and free cash flow. A large backlog is encouraging, but it only creates shareholder value if contracts translate into profitable delivery.


For me, the combination of strong order growth, improving cash generation and raised earnings guidance makes LHX the most convincing of the three right now.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment(1)

  • Top
  • Latest
  • Miaoj
    ·10-30 22:46
    thanks  for sharing
    Reply
    Report